Mainstay Medical Announces Publication of Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study in Chronic Low Back Pain Patients
22.11.2022 16:00:00 EET | Business Wire | Press release
Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ReActiv8®-C study. Patients implanted with ReActiv8 at Klinikum Itzehoe were consecutively included into this cohort if they presented with back pain ≥6 and no prior lumbar surgery. The one-year results, published in World Neurosurgery, showed that a majority of the 44 patients followed up with demonstrated statistically significant improvements in pain (NRS), disability (ODI) and quality of life (EQ-5D-5L).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005230/en/
(Graphic: Business Wire)
This interim analysis indicates that the response to ReActiv8 for these patients is durable and the benefits improve over time, consistent with both a restorative mechanism of action and the ReActiv8-B randomized clinical trial results.
Dr. Med. Ardeshir Ardeshiri, Head physician of the Spine Surgery Section of the Clinic for Trauma Surgery and Orthopedics, Klinikum Itzehoe, said: “These favorable real-world data are consistent with the ReActiv8-B study, which is extremely important for me in adopting new technologies. I am excited to continue offering restorative neurostimulation with ReActiv8 for my patients with multifidus dysfunction resulting in chronic axial low back pain.”
Jason Hannon, CEO of Mainstay Medical, said: "These real-world results further validate ReActiv8’s restorative mechanism of action, which treats a primary underlying cause of mechanical chronic lower back pain, multifidus dysfunction. German physicians have been some of our foremost implanters of ReActiv8, and we look forward to continuing to make the therapy more broadly available to patients in this region.”
Link to publication of the study Real-World Evidence for Restorative Neurostimulation in Chronic Low Back Pain—a Consecutive Cohort Study - ScienceDirect
About ReActiv8®
ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. Multifidus muscle dysfunction may be evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy, and who are not candidates for spine surgery. ReActiv8 has received regulatory approval in several geographic areas, and is commercially available in the European Economic Area, Australia, the UK, and the US.
About Mainstay Medical
Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation™ system, ReActiv8®, for people with disabling mechanical CLBP. Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.
Further information can be found at www.mainstaymedical.com .
Forward-Looking Statements
All statements in this announcement other than statements of historical fact are, or may be deemed to be, forward-looking statements. These forward-looking statements may include, without limitation, statements regarding the company’s intentions, beliefs or current expectations concerning, among other things, the company’s commercial efforts and performance, financial position, financing strategies, product design and development, regulatory applications and approvals, and reimbursement arrangements.
Forward-looking statements involve risk and uncertainty and are not guarantees of future performance. Actual results may differ materially from those described in, or suggested by, the forward-looking statements. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements herein, including, without limitation, the risks and uncertainties included in the company’s Annual Report for the year ended 31 December 2021, which should be read in conjunction with the company’s public disclosures (available on the company’s website ( www.mainstaymedical.com ). The forward-looking statements herein speak only as of the date of this announcement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005230/en/
Contact information
PR and IR Enquiries:
LifeSci Advisors, LLC
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: britchie@lifesciadvisors.com
FTI Consulting (for Ireland)
Jonathan Neilan or Patrick Berkery
Tel. : +353 1 765 0886
Email: mainstay@fticonsulting.com
Mainstay Medical
Corporate Communications
Email: Media@mainstaymedical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSG Helps Businesses Cut Fraud Losses by Up to 70% with CSG Payments Protection.ai3.2.2026 15:30:00 EET | Press release
As payments fraud accelerates with AI, businesses are racing to spot and block threats without slowing customers down. Today, CSG® (NASDAQ: CSGS) launched CSG Payments Protection.ai, a next-generation fraud detection and financial risk management solution to accurately identify and stop payment fraud. The solution proactively monitors digital transactions across diverse payment channels and fraud types, so businesses can reduce fraud losses by 50–70% while significantly lowering false-positive alerts and the resulting customer friction. “Fraud is no longer a once-in-a-while surprise,” said Saurabh Joshi, EVP and President, CSG Payments. “It’s constant, adaptive, and affects businesses regardless of size or industry. That’s why it was so important for us to offer an always‑learning AI solution that can help businesses stay ahead of increasingly sophisticated threats. With CSG Payments Protection.ai, we give our customers smarter protection, fewer false-positive declines, and a smoother
JTB Group Unveils its Long-Term Vision “OPEN FRONTIER 2035”3.2.2026 15:00:00 EET | Press release
JTB Group has unveiled “OPEN FRONTIER 2035,” its long-term vision for the next decade. The vision positions JTB as a frontier (leading-edge) enterprise that brings together people, places, businesses, and possibilities to create connections and generate new value for society. By pioneering a new era of Designing Human Moments, we will harness our expertise and insights to connect, create, and contribute to the world—enriching people’s lives with excitement and contentment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203174455/en/ JTB Group's Desired Vision for 2035 Our Source of Value is the Power to Create Connections JTB Group has positioned “Intelligence that Creates Connections” as the core of its competitive advantage. Insight and expertise—when combined and continuously enhanced—will enable the Group to create meaningful connections by bringing together people, places, businesses, and possibilities, thereby gener
Visa Direct and UnionPay International Will Extend Global Money Movement Network to Billions of Cards in Chinese Mainland3.2.2026 14:00:00 EET | Press release
At Web Summit Qatar, Visa (NYSE:V) and UnionPay International (UPI) announced an agreement to enable cross-border money movement into Chinese Mainland through Visa Direct. Once fully rolled out, clients will be able to send cross-border remittances and business-to-consumer payouts to more than 95 percent of UnionPay International debit cardholders in Chinese Mainland, through a single connection. By connecting Visa Direct’s global money movement network to UPI’s MoneyExpress platform, Visa will provide a more seamless, secure, and transparent way for consumers and businesses worldwide to send money into Chinese Mainland, one of the world’s largest remittance destinations. This milestone showcases Visa’s commitment to opening global corridors and extending reliable money movement capabilities to people and businesses worldwide. “Global business now moves at internet speed, but money hasn’t always kept pace,” said Vira Platonova, Global Head of Visa Direct. “By expanding Visa Direct’s re
China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA®3.2.2026 14:00:00 EET | Press release
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumor patients for treatment with KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy. This is the first Promega companion diagnostic to receive NMPA approval. “This approval represents a step toward more personalized and effective cancer treatment in China,” says Alok Sharma, Global Clinical Market Director at Promega. “We are proud to collaborate with pharmaceutical companies to deliver global solutions that expand access to innovative technologies and life-saving, effective therapies.” China continues to face one of the world’s highest cancer burdens, with solid tumors representing the vast majority of diagnoses nationwide. Despite advances in oncology care, most patients with advanced so
Rising Global Bullion Market Risks Are Forcing European Investors to Rethink Physical Gold Access3.2.2026 11:35:00 EET | Press release
As volatility reshapes global financial markets, European institutional investors are turning to safe-haven assets. While physical gold remains one of the world's most resilient and attractive store-of-value assets, secure and verifiable access to bullion has become increasingly difficult. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203826775/en/ Illustrative image of physical gold bullion bars. (Photo: AETOSWire) Recent industry developments have placed structural pressure on the gold market. Elevated price levels have heightened concerns around counterfeit bars, fragmented supply chains, and the complexity of cross-border custody. For European institutions operating under strict regulatory oversight, the challenge is no longer whether to allocate to gold — but how to do so safely, transparently, and within established compliance frameworks. To this end, Golden Ark Reserve, operated by Golden Ark General Trading (FZC)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom